Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Those who voluntarily signed the informed consent to participate in this study.~2. Adults aged 19 years or older.~3. Those diagnosed with type 2 diabetes mellitus.~4. Subjects taking constant doses of ≥1000mg of Metformin and 10 mg of Dapagliflozin for more than 8 weeks at Visit 1 (regardless of dosage forms (immediate-release and sustained-release) and single agent or combination drug.)~5. Subjects with 7% ≤ HbA1c ≤ 10.5% at Visit 1 and Visit 2~6. Subjects able to understand the study, comply with study procedures, and attend all scheduled visits.~Exclusion Criteria:~1. Uncontrolled hyperglycemia at Visit 1 or Visit 2 (subjects with FPG \> 270 mg/dL as a result of the test conducted by the study institution.)~2. Medication compliance is \<70% or \>120% for each BR3003D, BR3003C, BR3003A-2, and BR3003B-2 during the Run-in period at Visit 2.~3. Patients with other types of diabetes instead of type 2 diabetes (e.g., type 1 diabetes, secondary diabetes, or congenital renal glycosuria).~4. Patients with uncontrolled, severe diabetic complications (e.g., proliferative diabetic retinopathy uncontrolled despite medication and severe diabetic neuropathy)~5. Those who suffered from acute or chronic metabolic acidosis within 3 months as of Visit 1, including lactic acidosis and diabetic ketoacidosis.~6. Those with \> 40 kg/m2 of BMI measured at Visit 1.~7. Those with uncontrolled hypertension at Visit 1 or Visit 2 (SBP \> 180 mmHg or DBP \> 110 mmHg).~8. Those diagnosed with cardiovascular diseases (myocardial infarction, stroke, unstable angina, and transient ischemic attack (TIA)) or undergo revascularization within 3 months as of Visit 1~9. Those with heart failure (NYHA class II\~IV) or who had suffered from heart failure.~10. Those who suffered from gastrointestinal diseases that may affect the absorption, distribution, metabolism, and excretion of investigational products or had underwent surgery;~11. Those who underwent surgery requiring general anesthesia within 4 weeks as of Visit 1 or who are scheduled to receive such surgery within 4 weeks after the study ends~12. Those with a history of malignant tumor within 5 years as of Visit 1~13. Those who have a clinically significant liver disease~14. Those who have a clinically significant renal disease~15. Those with clinically significant hematuria detected at Visit 1 or Visit 2~16. Those with chronic diseases requiring the continued use of systemic steroid or immunosuppressants (oral administration, injection, or inhalation).~17. Patients with pituitary insufficiency or adrenal insufficiency.~18. Those with clinically significant severe infection or trauma based on an investigator's judgement.~19. Patients with AIDS.~20. Patients with acute or chronic diseases that may cause histotoxic hypoxia such as respiratory failure and shock.~21. Those who need treatment due to dehydration caused by persistent diarrhea and vomiting or at a risk of fluid volume depletion.~22. Those who have been administered with the following drugs or expected to require the continued administration during the study period:~    * Those administered with systemic steroid agents (Prednisolone, \>30 mg/day) within 2 weeks as of Visit 1.~   * Those being administered with thyroid medications and whose dose has been modified within 6 weeks as of Visit 1 (however, dose reduction is accepted.)~   * Those being administered with diuretics and whose dose has been modified within 8 weeks as of Visit 1 however, dose reduction is accepted.)~   * Those who have been administered with antidiabetics other than Metformin and Dapagliflozin within 8 weeks as of Visit 1.~   * Those who have been administered with obesity drugs (e.g., phentermine, phendimetrazine, diethylpropion, and mazindol) within 12 weeks as of Visit 1.~   * Those who need to take prohibited concomitant medications stated here during the study period.~23. Those with history of alcohol or drug abuse within 1 year as of Visit 1.~24. Those who had allergic reaction to main ingredients or components of the investigational products.~25. Those who had genetic disorders such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption.~26. Females who are pregnant or breastfeeding.~27. Patients planning to become pregnant or of childbearing potential, but not using any recognized contraceptive method~28. Those who are currently participating in other ongoing clinical studies or those who have taken the investigational products from other clinical studies within 12 weeks as of Visit 1~29. Those who are judged unsuitable for the study by a principal investigator or investigators.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg + Pioglitazone 30mg Placebo (Type: EXPERIMENTAL): Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 15mg Pioglitazone 30mg placebo
- Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 30mg +Pioglitazone 15mg Placebo (Type: EXPERIMENTAL): Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 30mg Pioglitazone 15mg placebo
- Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg Placebo+ Pioglitazone 30mg Placebo (Type: ACTIVE_COMPARATOR): Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 15mg placebo Pioglitazone 30mg placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).